More positive vaacine news this AM

1,893 Views | 7 Replies | Last: 5 yr ago by DadHammer
Windy City Ag
How long do you want to ignore this user?
AG
Pfizer/BioNtech and Oxford/AstraZeneca both published positive updates.

Oxford just hit the wire. . . "very good immune responses not just on nuetralizing antibodies but of T-Cells a well"

https://www.cnbc.com/2020/07/20/oxford-universitys-coronavirus-vaccine-shows-positive-immune-response-in-an-early-trial.html

Pfizer news is here

https://www.cnbc.com/2020/07/20/pfizer-and-biontechs-potential-coronavirus-vaccine-shows-promise.html

cone
How long do you want to ignore this user?
AG
I want that Oxford vaccine
amercer
How long do you want to ignore this user?
AG
A lot of good news this morning.

https://www.fiercebiotech.com/
buffalo chip
How long do you want to ignore this user?
S
"not statistically significant"...

But, the stock goes up 300% in morning trading.

Too early to be able to tell on this one, but charlatans will take advantage of the public's desire for good news...
Player To Be Named Later
How long do you want to ignore this user?
AG
buffalo chip said:

"not statistically significant"...

But, the stock goes up 300% in morning trading.

Too early to be able to tell on this one, but charlatans will take advantage of the public's desire for good news...
Buy the rumor, sell the news

amercer
How long do you want to ignore this user?
AG
P value less than 0.05. Might not hold up in a bigger trial but not total bull**** at this point.
DadHammer
How long do you want to ignore this user?
AG
cone said:

I want that Oxford vaccine
You snob you!!!









Just to be sure, you know I'm kidding.... Its Oxford.
cone
How long do you want to ignore this user?
AG
this is why they're doing the challenge trial

it works they know it works above the FDA threshold and they need to get it through phase 3 asap
DadHammer
How long do you want to ignore this user?
AG
Excellent
Refresh
Page 1 of 1
 
×
subscribe Verify your student status
See Subscription Benefits
Trial only available to users who have never subscribed or participated in a previous trial.